These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33742366)

  • 1. Meta-analysis of Safety and Efficacy of Anticoagulation versus no Anticoagulation in Octogenarians and Nonagenarians with Atrial Fibrillation.
    Barssoum K; Kumar A; Thakkar S; Sheth AR; Kharsa A; Ibrahim M; Rai D; Idemudia O; Akula N; Patel HP; Mowafy A; Elkaryoni A; Ibrahim F; Mubasher M; Ghattas KN; Rao M
    High Blood Press Cardiovasc Prev; 2021 May; 28(3):271-282. PubMed ID: 33742366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Bleeding Risk and Frailty Status on Anticoagulation Patterns in Octogenarians With Atrial Fibrillation: The FRAIL-AF Study.
    Lefebvre MC; St-Onge M; Glazer-Cavanagh M; Bell L; Kha Nguyen JN; Viet-Quoc Nguyen P; Tannenbaum C
    Can J Cardiol; 2016 Feb; 32(2):169-76. PubMed ID: 26277091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
    Bin Abdulhak AA; Khan AR; Tleyjeh IM; Spertus JA; Sanders SU; Steigerwalt KE; Garbati MA; Bahmaid RA; Wimmer AP
    Europace; 2013 Oct; 15(10):1412-20. PubMed ID: 23954918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of safety and efficacy of oral anticoagulants in patients requiring catheter ablation for atrial fibrillation.
    Rahman H; Khan SU; DePersis M; Hammad T; Nasir F; Kaluski E
    Cardiovasc Revasc Med; 2019 Feb; 20(2):147-152. PubMed ID: 29786530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: A systematic review and meta-analysis.
    Romero J; Cerrud-Rodriguez RC; Diaz JC; Rodriguez D; Arshad S; Alviz I; Cerna L; Rios S; Monhanty S; Natale A; Garcia MJ; Di Biase L
    J Cardiovasc Electrophysiol; 2019 Aug; 30(8):1250-1257. PubMed ID: 31257677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: A systematic review and meta-analysis.
    Kuo HC; Liu FL; Chen JT; Cherng YG; Tam KW; Tai YH
    Clin Cardiol; 2020 May; 43(5):441-449. PubMed ID: 31944351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restarting of anticoagulation in patients with atrial fibrillation after major bleeding: A meta-analysis.
    Zhou Y; Guo Y; Liu D; Feng H; Liu J
    J Clin Pharm Ther; 2020 Aug; 45(4):591-601. PubMed ID: 32181518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uninterrupted versus interrupted direct oral anticoagulation for catheter ablation of atrial fibrillation: A systematic review and meta-analysis.
    Asad ZUA; Akhtar KH; Jafry AH; Khan MH; Khan MS; Munir MB; Lakkireddy DR; Gopinathannair R
    J Cardiovasc Electrophysiol; 2021 Jul; 32(7):1995-2004. PubMed ID: 33861494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies.
    Brunetti ND; Tricarico L; Tilz RR; Heeger CH; De Gennaro L; Correale M; Ieva R; Di Biase M; Rillig A; Metzner A; Santoro F
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):209-214. PubMed ID: 32080786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists.
    Abumuaileq RR; Abu-Assi E; Raposeiras-Roubin S; López-López A; Redondo-Diéguez A; Álvarez-Iglesias D; Rodríguez-Mañero M; Peña-Gil C; González-Juanatey JR
    Europace; 2015 May; 17(5):711-7. PubMed ID: 25662984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis.
    Vestergaard AS; Skjøth F; Larsen TB; Ehlers LH
    PLoS One; 2017; 12(11):e0188482. PubMed ID: 29155884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry.
    Königsbrügge O; Simon A; Domanovits H; Pabinger I; Ay C
    BMC Cardiovasc Disord; 2016 Dec; 16(1):254. PubMed ID: 27938343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
    Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R
    J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Escobar C; Barrios V; Jimenez D
    Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.
    Zhu WG; Xiong QM; Hong K
    Tex Heart Inst J; 2015 Feb; 42(1):6-15. PubMed ID: 25873792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.